Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnos...
November 04 2020 - 07:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or transection
to peripheral nerves, today announced that Karen Zaderej, chairman,
CEO, and president, will present at two upcoming investor events –
the Jefferies Virtual London Healthcare Conference and the
Canaccord Genuity Virtual MedTech & Diagnostics Forum.
Ms. Zaderej will present at the Jefferies London
Healthcare Conference on Wednesday, November 18, 2020 at 3:15 p.m.
(10:15 a.m. ET).
She will present at the Canaccord Genuity Virtual
MedTech & Diagnostics Forum on Thursday, November 19, 2020 at
10:00 a.m. ET.
Both presentations will be webcast live and
accessible through the Investors page at www.axogeninc.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.axogeninc.com.
About
AxogenAxogen (AXGN) is
the leading company focused specifically on the science,
development and commercialization of technologies for peripheral
nerve regeneration and repair. Axogen employees are passionate
about helping to restore peripheral nerve function and quality of
life to patients with physical damage or transection to peripheral
nerves by providing innovative, clinically proven and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; Axoguard® Nerve Cap, a
porcine submucosa ECM product used to protect a peripheral nerve
end and separate the nerve from the surrounding environment to
reduce the development of symptomatic or painful neuroma; and
Avive® Soft Tissue Membrane, a processed human umbilical cord
intended for surgical use as a resorbable soft tissue barrier. The
Axogen portfolio of products is available in the United States,
Canada, the United Kingdom, South Korea, and several other European
and international countries.
Contact:Axogen, Inc.Peter J. Mariani, chief financial
officerpmariani@axogeninc.comInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2023 to Mar 2024